These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 31374878)

  • 1. CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?
    Musielak B; Kocik J; Skalniak L; Magiera-Mularz K; Sala D; Czub M; Stec M; Siedlar M; Holak TA; Plewka J
    Molecules; 2019 Aug; 24(15):. PubMed ID: 31374878
    [No Abstract]   [Full Text] [Related]  

  • 2. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
    Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
    Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules.
    Yang J; Hu L
    Med Res Rev; 2019 Jan; 39(1):265-301. PubMed ID: 30215856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective.
    Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M
    Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors.
    Ganesan A; Ahmed M; Okoye I; Arutyunova E; Babu D; Turnbull WL; Kundu JK; Shields J; Agopsowicz KC; Xu L; Tabana Y; Srivastava N; Zhang G; Moon TC; Belovodskiy A; Hena M; Kandadai AS; Hosseini SN; Hitt M; Walker J; Smylie M; West FG; Siraki AG; Lemieux MJ; Elahi S; Nieman JA; Tyrrell DL; Houghton M; Barakat K
    Sci Rep; 2019 Aug; 9(1):12392. PubMed ID: 31455818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint.
    Konieczny M; Musielak B; Kocik J; Skalniak L; Sala D; Czub M; Magiera-Mularz K; Rodriguez I; Myrcha M; Stec M; Siedlar M; Holak TA; Plewka J
    J Med Chem; 2020 Oct; 63(19):11271-11285. PubMed ID: 32936638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
    Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
    Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
    Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
    Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
    Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
    Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
    Chen R; Yuan D; Ma J
    Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-based screening of programmed death ligand 1 (PD-L1).
    Perry E; Mills JJ; Zhao B; Wang F; Sun Q; Christov PP; Tarr JC; Rietz TA; Olejniczak ET; Lee T; Fesik S
    Bioorg Med Chem Lett; 2019 Mar; 29(6):786-790. PubMed ID: 30728114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
    Lin X; Lu X; Luo G; Xiang H
    Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide.
    Niu B; Appleby TC; Wang R; Morar M; Voight J; Villaseñor AG; Clancy S; Wise S; Belzile JP; Papalia G; Wong M; Brendza KM; Lad L; Gross ML
    Biochemistry; 2020 Feb; 59(4):541-551. PubMed ID: 31841311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.
    Liu H; Bi X; Zhou Y; Shi R; Yao S; Qi J; Feng H; Feng M; Yan J; Tan S
    Signal Transduct Target Ther; 2020 Aug; 5(1):158. PubMed ID: 32839442
    [No Abstract]   [Full Text] [Related]  

  • 15. Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways.
    Sasikumar PG; Ramachandra M
    BioDrugs; 2018 Oct; 32(5):481-497. PubMed ID: 30168070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of kinase inhibitors downregulating PD-L1 expression via on/in cell quantitative immunoblots.
    Xie Y; Ding J; Cui X; Wu M; Huang C; Zhang R; Wang J; Li X; Cen S; Zhou J
    Eur J Pharm Sci; 2020 Jan; 142():105088. PubMed ID: 31626963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction.
    Klimek J; Kruc O; Ceklarz J; Kamińska B; Musielak B; van der Straat R; Dӧmling A; Holak TA; Muszak D; Kalinowska-Tłuścik J; Skalniak Ł; Surmiak E
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.
    Sasmal P; Kumar Babasahib S; Prashantha Kumar BR; Manjunathaiah Raghavendra N
    Bioorg Med Chem; 2022 Nov; 73():117001. PubMed ID: 36126447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
    Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA
    J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.